注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Amarin Corporation PLC是一家制药公司。该公司专注于改善心血管(CV)、健康和降低CV风险的疗法的商业化和开发。该公司通过VASCEPA的开发和商业化运营。其主导产品Vasicpa(icosapent ethyl)胶囊被用作饮食的辅助药物,以降低患有严重高甘油三酯血症的成年患者的甘油三酯水平。Vascepa的这一适应症被称为MARINE适应症,主要基于Vascepa在该获批患者群体中的MARINE研究结果。该公司主要将Vascepa销售给批发商以及选定的区域批发商和专业药房供应商,或统称为其分销商,后者又将Vascepa转售给零售药店,再转售给患者和医疗保健提供者。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Odysseas D. Kostas | 48 | 2023 | Independent Non-Executive Chairperson of the Board |
John Climax | 70 | 2006 | Chairman of Scientific Advisory Board |
Mark W. Pierce | - | 2006 | Member of the Scientific Advisory Board |
Reid Patterson | - | 2006 | Member of the Scientific Advisory Board |
Jan D. Wallace | 82 | 2006 | Member of Scientific Advisory Board |
Mark Anthony DiPaolo | 51 | 2023 | Independent Non-Executive Director |
Patrice Eadon Bonfiglio | 40 | 2023 | Independent Non-Executive Director |
Diane E. Sullivan | 60 | 2023 | Independent Non-Executive Director |
Oliver O'Connor | 61 | 2023 | Independent Non-Executive Director |
Paul Cohen | 48 | 2023 | Independent Non-Executive Director |
Louis E. Sterling | 43 | 2023 | Independent Non-Executive Director |
Keith L. Horn | 64 | 2023 | Independent Non-Executive Director |
Patrick Holt | - | 2023 | President, CEO & Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核